For decades, oral health care has mainly focused on preventing cavities and gum disease. However, scientific research has ...

At AAPA 2025, researchers present the results of a PA-led quality improvement initiative for patients with head and neck cancer.

PCP2, can effectively measure PD-L1 expression in patients with head and neck cancers, outperforming the conventional tracer ...

Key Takeaways Keytruda is approved for resectable locally advanced head and neck squamous cell carcinoma with PD-L1 expression, marking a significant advancement in treatment options. The KEYNOTE-689 ...

Source Reference: Bryan ME, et al "Direct comparison of alternative blood-based approaches for early detection and diagnosis of HPV-associated head and neck cancers" Clin Cancer Res 2025; DOI: 10. ...

Company News Published 06/18/2025, 09:09 AM 0 CEL-SCI applauds FDA approval of Merck’s Keytruda for head and neck cancer CVM -1.19% ...

HMC hosts first patient event to support head and neck cancer survivors Published: 15 Jun 2025 - 08:49 am | Last Updated: 15 Jun 2025 - 08:59 am ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous ...

The Rahway, N.J., drug maker said Friday that its treatment, Keytruda, has been approved for adult patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express ...

New drugs take too long to get to market because of clinical trial bottlenecks. Two cancer doctors built AI-enabled tech to ...

The FDA has started a priority review of MSD's Keytruda as neoadjuvant and adjuvant treatment of locally advanced head and neck squamous cell carcinoma (HNSCC), with a decision due by 23rd June ...

This trial was looking at a treatment called Reolysin in combination with paclitaxel and carboplatin chemotherapy for advanced cancers, including head and neck cancers. Doctors often treat advanced ...